Hepatocellular Carcinoma Risk Scores: Ready to Use in 2015?
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Wu H, Yang H, Wang Q, Chen C, Santella R Carcinogenesis. 2017; 38(10):1021-1028.
PMID: 28981677 PMC: 5862336. DOI: 10.1093/carcin/bgx078.
References
1.
Fontana R, Dienstag J, Bonkovsky H, Sterling R, Naishadham D, Goodman Z
. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut. 2010; 59(10):1401-9.
PMC: 3740000.
DOI: 10.1136/gut.2010.207423.
View
2.
Huang Y, Jen C, Yang H, Lee M, Su J, Lu S
. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol. 2011; 29(27):3643-50.
PMC: 4874144.
DOI: 10.1200/JCO.2011.36.2335.
View
3.
Lee M, Yang H, Lu S, Jen C, You S, Wang L
. Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma. Int J Cancer. 2014; 135(5):1119-26.
DOI: 10.1002/ijc.28753.
View
4.
Wong V, Chan S, Mo F, Chan T, Loong H, Wong G
. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010; 28(10):1660-5.
DOI: 10.1200/JCO.2009.26.2675.
View
5.
Yuen M, Tanaka Y, Fong D, Fung J, Wong D, Yuen J
. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2008; 50(1):80-8.
DOI: 10.1016/j.jhep.2008.07.023.
View